Propanc Advances PRP Toward Clinical Trials for Pancreatic Cancer

Australia-based Propanc Biopharma (Propanc) announced on March 12, 2026 that it is positioning its lead investigational therapy, PRP, to address the global pancreatic cancer treatment market as the program advances toward early clinical development. The company said the therapy could target a market exceeding $3 billion while addressing persistent unmet need in a disease characterized by aggressive progression and limited treatment options.¹

PRP is a proenzyme-based therapy composed of trypsinogen and chymotrypsinogen. It is designed to influence tumor progression by targeting biological pathways associated with metastasis and tumor growth. According to the company, the therapy is intended to affect processes linked to cancer stem cell activity, angiogenesis, and tumor invasion. These mechanisms are widely recognized as drivers of pancreatic cancer progression.¹

Pancreatic cancer remains one of the most lethal malignancies, largely because it is often diagnosed at advanced stages and rapidly develops metastatic disease. These challenges have prompted growing interest in therapeutic strategies aimed at disrupting metastasis and modifying tumor microenvironment signaling rather than relying solely on conventional cytotoxic approaches.²

How is the company preparing PRP for first-in-human clinical evaluation?

The announcement builds on a related development disclosed on March 10, 2026, when Propanc executed a service agreement with Germany-based contract development organization FyoniBio to develop and validate a pharmacokinetic (PK) assay for PRP.³ The assay will support the company’s planned Phase Ib first-in-human study evaluating the therapy in patients with advanced solid tumors.

Validated bioanalytical methods are a critical requirement in early-stage clinical development. PK assays enable investigators to measure how a therapy is absorbed, distributed, metabolized, and cleared in the body, generating data needed to support dose selection and regulatory documentation.⁴

The planned Phase Ib study is expected to enroll approximately 30 to 40 patients and is designed primarily to evaluate safety and determine appropriate dosing levels while also generating preliminary signals of biological activity.³

“Establishing and validating our PK method for the [first-in-human] study is one of three key activities in preparation for this pivotal milestone,” said Ralf Brandt, PhD, director of R&D at Propanc, in a company press release.³ “The other two are the GMP [good manufacturing practice] manufacture of PRP and clinical trial application for the study, which we are actively undertaking.”

What preclinical data support development of PRP in pancreatic cancer?

Earlier preclinical findings provide insight into the scientific rationale behind PRP’s development. According to results reported by Propanc in early March 2026, laboratory studies evaluating the therapy in pancreatic cancer models demonstrated greater than 85% tumor growth inhibition.⁵

Unlike traditional chemotherapy, which targets rapidly dividing cells, PRP is designed to influence tumor biology by interfering with pathways associated with metastasis and tumor microenvironment regulation. Preclinical studies suggest the therapy may suppress epithelial–mesenchymal transition and angiogenesis, two processes closely linked to tumor invasion and metastatic spread.⁵

The therapy has also received orphan drug designation from FDA for pancreatic cancer, a regulatory designation intended to support development of therapies addressing rare diseases or areas of significant unmet medical need.⁵

Why are metastasis-targeting therapies attracting industry attention?

Pancreatic cancer continues to present major challenges for drug developers, as existing treatments often produce limited survival benefit and significant toxicity. As a result, researchers are increasingly exploring therapies designed to alter the biological processes that enable tumor spread.²

For the biopharmaceutical industry, programs such as PRP illustrate a broader shift toward multi-mechanism strategies that attempt to modify tumor biology rather than relying exclusively on cytotoxic effects. As the program moves toward clinical evaluation, Propanc’s development pathway highlights the operational and scientific steps required to translate promising preclinical findings into investigational therapies targeting cancers that have historically resisted conventional treatment approaches.

References

1. Propanc Biopharma. Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy. Press Release. March 12, 2026.
2. Sarantis P, Koustas E, Papadimitropoulou A, Papavassiliou AG, Karamouzis MV. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. World J Gastrointest Oncol. 2020;12(2):173-181. doi: 10.4251/wjgo.v12.i2.173
3. Propanc Biopharma. Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study. Press Release. March 10, 2026.
4. FDA. Guidance for Industry, Bioanalytical Method Validation Guidance for Industry (CDER, May 2018).
5. Propanc Biopharma. Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models. Press Release. March 3, 2026.